Our conditionally-activated tri-specific antibody platform, engaging both T cells and NK cells while a proprietary cap confines immune activation to the tumor microenvironment.
Two candidates are in development: IM1240 (capped CD3x5T4xNKG2A), advancing toward the clinic, and IM1305 (capped CD3xTROP2xNKG2A), in preclinical development.
A first-in-class monoclonal antibody targeting CEACAM1. CM24 has completed a randomized Phase 2 study in second-line pancreatic cancer with positive results across all efficacy endpoints and a validated biomarker strategy. Available for partnering.
A first-in-class small molecule targeting both IRS1/2 and STAT3, major drug-resistance pathways in hard-to-treat cancers. Phase 1 dose escalation is complete, with a recommended Phase 2 dose established. Available for partnering.